Replies to post #303076 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

TempePhil..BRILLIANT WORK_POSTING...MANY THANKS

[rayovacAAA]

100% WRONG!!!!!!!

From Lilly's PR, "Specifically, at 76 weeks compared to baseline, treatment with donanemab slowed decline by 32 percent compared to placebo as measured by the iADRS, which was statistically significant. "

Slowed decline by 32 percent compared to placebo, means it still declined 68%.

SLOWED DECLINE BY 32 PERCENT COMPARED TO PLACEBO DOES NOT EQUATE TO A 68% DECLINE FROM BASELINE!!!!!


GOOD LUCK AND GOD BLESS!!!!!

[rayovacAAA]

HOW DID THE 32 A2-73 PATIENTS COMPARED TO PLACEBO?????

From Lilly's PR, "Specifically, at 76 weeks compared to baseline, treatment with donanemab slowed decline by 32 percent compared to placebo as measured by the iADRS, which was statistically significant. "

GOOD LUCK AND AND GOD BLESS!!!!!!!

[vg_future]

TempePhil, thanks for the comparative analysis. Very well put. It is only matter of time before the world finds/accepts the benefits of Anavex’s drug.

-vg_future

[RedShoulder]

Anavex vs Lilly's drug. As they say "a picture is worth a thousands words". Many thanks TempePhil for working up this single graph with both Anavex's and Lilly's drug on the same graphic. A beautiful sight for Anavex share holders. Well done Phil.

Lilly donanemab versus A273 comparison. Graphically shown below!

From Lilly's PR, "Specifically, at 76 weeks compared to baseline, treatment with donanemab slowed decline by 32 percent compared to placebo as measured by the iADRS, which was statistically significant. "

Slowed decline by 32 percent compared to placebo, means it still declined 68%.
Compare this to Anavex's, peer reviewed "..Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study", figure 2b, where all high dose patients declined 1 ADCS-ADL point, versus the low/medium dose (assumed to be at least placebo or no dose) of -25 points at 148 weeks.
High dose patients declined 4% of what the low/medium dose patients declined.
Or as Lilly's PR would say, for high dose patients, A2-73 SLOWED declined by 96%!
Plotting Lilly's donandmab result, 68% decline (68% of 25 is 17), on the Anavex Figure 2b.

(See referrenced post, I could not copy the graph complied by TempePhil)

In the donanemab arm, 30.5 percent of patients discontinued treatment due to an adverse event and half of these discontinuations were due to ARIA-related events.
Microhemorrhages (7.6 percent) and superficial siderosis of central nervous system (13.7 percent), nausea (10.7 percent), and infusion-related reaction (IRR) (7.6 percent).
Superficial hemosiderosis of the central nervous system is a disease of the brain resulting from chronic iron deposition in neuronal tissues associated with cerebrospinal fluid.
A2-73 is administered as a pill, while donanemab is delivered by IV (from which 7.6% of patients discontinued because of infusion-related reaction!
The siderosis is definitely not good, and the infusion-related reaction of 7.6% seems suprisingly high.

There is a clear winner, A2-73.

[powerwalker]

Wonderful piece of work, TP, and thanks.

I told the director of our parish's Senior Adult Day Care Center, mostly early AD folks, not to believe any of the Lilly crap (we're in northern Indiana) and that Anavex is getting closer. I'll pass along your graph to her.

Thank you again, TP.



ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES ... and for Joe RIGHT NOW!!!

[attilathehunt]

Great Chart!!!!

[frrol]

Your "68%" is mathematically false, but your inference that Donenenab has inferior effect compared to 2-73 for ADCS-ADL is supportable. Though of course you have to take into account that Lily's trial was far larger and more robust.

I would not be surprised to see that 2-73 is in fact superior for that metric in AD. We'll know better in 2022.